Skip to main content
Erschienen in: Journal of the International AIDS Society 4/2010

Open Access 01.11.2010 | Poster presentation

Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients

verfasst von: J Moltó, M Valle, C Miranda, S Cedeño, E Negredo, MJ Barbanoj, B Clotet

Erschienen in: Journal of the International AIDS Society | Sonderheft 4/2010

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Purpose of the study

To investigate the potential of a commonly used botanical supplement, Echinacea purpurea, to interact with the boosted protease inhibitor darunavir/ritonavir.

Methods

Open-label, fixed-sequence study in 15 HIV-infected patients receiving antiretroviral therapy including darunavir/ritonavir (600/100 mg twice daily) for at least 4 weeks. Echinacea purpurea root extract-containing capsules were added to the antiretroviral treatment (500 mg every 6 hours) from days 1 to 14. Darunavir concentrations in plasma were determined by using HPLC immediately before and 1, 2, 4, 6, 8, 10 and 12 hours after a morning dose of darunavir/ritonavir on days 0 (darunavir/ritonavir) and 14 (darunavir/ritonavir + echinacea). Individual darunavir pharmacokinetic parameters were calculated by using non-compartmental analysis, and were compared between days 0 and 14 by using the geometric mean ratio (GMR) and its 95% confidence interval (95% CI).

Results

Median (range) age was 49 (43-67) years, and body mass index was 24.2 (18.7-27.5) kg/m2. Echinacea was well tolerated and all participants completed the study. Relative to administration of darunavir/ritonavir alone, its coadministration with Echinacea purpurea resulted in little change in darunavir pharmacokinetic parameters. Table 1
Table 1
 
DRV/r
DRV/r + Echinacea
GMR (95% CI)
p
Cτ (ng/mL)
2.1 (1.6-2.7)
1.7 (1.4-2.2)
0.84 (0.59-1.19)
0.311
AUCτ (ng.h/mL)
46.2 (39.0-54.7)
41.6 (35.1-49.2)
0.90 (0.71-1.14)
0.374
Cmax (ng/mL)
6.4 (5.5-7.4)
6.2 (5.3-7.25)
0.98 (0.79-1.21)
0.810

Conclusions

coadministration of Echinacea purpurea with darunavir/ritonavir was safe and well tolerated in HIV-infected patients; data suggest that no dose adjustment for darunavir/ritonavir is necessary.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Metadaten
Titel
Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
verfasst von
J Moltó
M Valle
C Miranda
S Cedeño
E Negredo
MJ Barbanoj
B Clotet
Publikationsdatum
01.11.2010
Verlag
BioMed Central
Erschienen in
Journal of the International AIDS Society / Ausgabe Sonderheft 4/2010
Elektronische ISSN: 1758-2652
DOI
https://doi.org/10.1186/1758-2652-13-S4-P187

Weitere Artikel der Sonderheft 4/2010

Journal of the International AIDS Society 4/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.